Epotin (epoetin alfa biosimilar) / Claris - LARVOL DELTA

A Case of Dialysis-Dependent Rapidly Progressing C3 Glomerulonephritis (KIDNEY WEEK 2023) - "Baseline Hb was lower in Eprex vs. Epotin group (9.9±1.3 g/dL vs. 10.8±1.3g/dL respectively) (p = 0.006). Conclusion Biosimilar epoetin® showed therapeutic equivalence with lower cost compared to originator drug (Eprex®) in maintaining Hb to target level in ESRD patients on HD. Trend of mean Hb level in both groups over the study (6 months)"

Clinical • Anemia • Chronic Kidney Disease • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Lupus Nephritis • Nephrology • Renal Disease

Assessment of iron metabolism disorders and adequate treatment of anemic syndrome in patients with breast cancer on the background of adjuvant chemotherapy. (PubMed, Klin Lab Diagn) - "AC correction was performed (ferinject, epotin-alpha, B12). The rational use of iron preparations, vitamins, and recombinant forms of EPO made it possible to restore Fe metabolism, stabilize the hemoglobin level, and also improve the condition of most breast cancer patients. The obtained data on IL-6, GP25, CRP indicate a certain relationship between them in the development of anemia with VDF in breast cancer patients and the need for further study of the characteristics of iron metabolism in cancer patients."

Journal • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • Metabolic Disorders • Oncology • Solid Tumor • HER-2 • IL6

Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®. (PubMed, J Pharm Biomed Anal) - "Jimaixin™ and Epotin™ presented also a lower amount of fully sialylated forms. HILIC method also showed that O-acetylation level of sialic acid residues might vary from one rEPO to the other."

Journal • EPO

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (clinicaltrials.gov) - P3; N=941; Completed; Sponsor: University of Washington; Active, not recruiting ➔ Completed

Trial completion

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (clinicaltrials.gov) - P3; N=941; Active, not recruiting; Sponsor: University of Washington; Trial completion date: Dec 2018 ➔ Mar 2020

Trial completion date